In summary, targeted inhibitors of the PD-L1-PI3K-AKT-mTOR pathway in our APDOs exhibited remarkable efficacy in impeding tumor growth, thereby positioning this pathway as a promising therapeutic target for this aggressive malignancy. The gene discussed is AKT1; the disease is neoplasm.